INNER CITY ASTHMA CONSORTIUM, ASTHMA CONTROL EVALUATION (ACE)

内城哮喘协会，哮喘控制评估 (ACE)

• 批准号: 7608371
• 负责人: STEPHEN John TEACH
• 金额: $ 9.88万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608371
• 关键词: Adherence; Allergens; Asthma; Biological Markers; Characteristics; Child; Clinical Management; Clinical Treatment; Computer Retrieval of Information on Scientific Projects Database; Devices; Education; Evaluation; Exhalation; Funding; Grant; Guidelines; Immune; Immunomodulators; Inflammation; Institution; Investigation; Low income; Measurement; Measures; Monitor; National Institute of Allergy and Infectious Disease; Nitric Oxide; Pathogenesis; Pharmaceutical Preparations; Pharmacogenetics; Prevention; Prevention program; Protocols documentation; Research; Research Personnel; Resources; Role; Source; Symptoms; Therapeutic; Treatment Protocols; United States National Institutes of Health; anti-IgE; base; design; improved; inner city; medication compliance

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of the National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium (ICAC) are (1) to identify forms of immune-based therapy to promote control and prevention of asthma, (2) to design protocols to evaluate immune-based therapies in the treatment of asthma in low-income inner-city children, and (3) to determine mechanisms of immune-based therapies and the potential unique mechanisms of asthma pathogenesis in low-income inner-city children by the conduct of parallel mechanistic investigations with the therapeutic protocols.The National Asthma Education and Prevention Program (NAEPP) asthma guidelines will change with further understanding of the pathogenesis of asthma, the introduction of new medications including immunomodulators, such as anti-IgE, and the potential application of biomarkers and pharmacogenetics in the clinical management of asthma. One of the additional measures proposed in this study is the use of biomarkers, specifically the measurement of exhaled nitric oxide (eNO) using the Aerocrine NIOX device. eNO can easily be measured in less than 15 minutes. It is anticipated that using eNO measurements in addition to using the NAEPP guidelines will enhance the level of assessment of asthma, guide medication regimens, and improve overall asthma control. Studies support the role of eNO in the clinical treatment of asthma, as an added approach to improve asthma control. Exhaled nitric oxide could serve as a monitor of poor asthma control due to poor symptom recognition, poor medication adherence, and persistent inflammation. The study results may change the paradigm of management for children with persistent asthma, which could be particularly beneficial for inner city asthma children where there appear to be unique characteristics, such as allergen exposure and poor adherence to therapy, that result in persistent inflammation.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 国家过敏和传染病研究所内城哮喘联盟 (ICAC) 的目标是 (1) 确定基于免疫的治疗形式，以促进哮喘的控制和预防，(2) 设计评估基于免疫的治疗的方案低收入内城儿童哮喘的治疗，以及（3）通过与以下机构进行平行机制研究，确定低收入内城儿童的免疫治疗机制和哮喘发病机制的潜在独特机制这随着对哮喘发病机制的进一步了解、包括免疫调节剂（如抗 IgE）在内的新药物的引入，以及生物标志物和药物遗传学在哮喘中的潜在应用，国家哮喘教育和预防计划 (NAEPP) 哮喘指南将发生变化。哮喘的临床管理。本研究提出的附加措施之一是使用生物标记物，特别是使用 Aerocrine NIOX 装置测量呼出一氧化氮 (eNO)。 eNO 可在 15 分钟内轻松测量。预计除了使用 NAEPP 指南之外，使用 eNO 测量将提高哮喘的评估水平，指导药物治疗方案并改善总体哮喘控制。 研究支持 eNO 在哮喘临床治疗中的作用，作为改善哮喘控制的补充方法。由于症状识别不佳、药物依从性差和持续炎症，呼出的一氧化氮可以作为哮喘控制不良的监测器。该研究结果可能会改变持续性哮喘儿童的治疗模式，这对于内城区哮喘儿童特别有益，因为这些儿童似乎具有独特的特征，例如接触过敏原和治疗依从性差，从而导致持续性炎症。